SOLVE FSHD, a venture philanthropic organization established to catalyze innovation in Facioscapulohumeral muscular dystrophy (FSHD) research, is partnering with the nonprofit organization XPRIZE Foundation to host a global competition to… Read More »
XPRIZE for FSHD research
Changemaker: Archer Sverdrup
Building an early-onset community Meet Archer Sverdrup, a St. Louis native with a love for power soccer, arts and crafts, and hanging out with their loyal German Shepherd, Blue. Archer… Read More »
Avidity begins Cohort C enrollment in FORTITUDE trial
Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD… Read More »
Aging in place – Tips for planning ahead
Notes by Helen Cave on behalf of the Wellness Hour Life brings change. Life would be boring if it didn’t encompass change. Yet the changes that FSHD brings to us… Read More »
A note to our families from CEO Mark Stone
A note to our families This morning, Fulcrum released top-line results of its phase 3 trial for Losmapimod. The results showed no difference between placebo and active ingredient groups. Therefore,… Read More »